Sandra Ghelardoni

University of Pisa — Italy

Medicine · Health Sciences

20h-index1.3kcitations115works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nitric Oxide and Endothelin Effects(28), Cardiac electrophysiology and arrhythmias(21), Ion channel regulation and function(17), Thyroid Disorders and Treatments(15), Cancer, Hypoxia, and Metabolism(15)

Publications115 total

Corrigendum “Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway” [Biomed. Pharmacother. 178 (2024), 117278]
Biomedicine & Pharmacotherapy·2026Open Access
Exercise pulmonary hypertension in chronic thromboembolic pulmonary disease without resting pulmonary hypertension: A systematic review and meta-analysis
Vascular Pharmacology·2026
Circulating microRNAs in pulmonary arterial hypertension: biomarkers for diagnosis, prognostic stratification, and treatment
GeroScience·2026· 1 cited
Sotatercept: A Crosstalk Between Pathways and Activities in the Pulmonary Circulation and Blood
International Journal of Molecular Sciences·2025· 5 citedOpen Access
Sotatercept: A Crosstalk Between Pathways and Activities in the Pulmonary Circulation and Blood
Preprints.org·2025Open Access
Ambrisentan Retains Its Pro‐Autophagic Activity on Human Pulmonary Artery Endothelial Cells Exposed to Hypoxia in an In Vitro Model Mimicking Diabetes
Journal of Cellular and Molecular Medicine·2025· 1 citedOpen Access
Sotatercept in pulmonary hypertension and beyond
European Journal of Clinical Investigation·2025· 3 citedOpen Access
Ambrisentan reverses the prosenescent and anti-autophagic effect of high glucose on human pulmonary artery endothelial cells exposed to hypoxia
European Heart Journal·2024Open Access
Unravel novel therapeutic targets in heart failure and associated pulmonary hypertension
European Heart Journal·2024
Development and primary characterization of a human thyroid organoid in vitro model for thyroid metabolism investigation
Molecular and Cellular Endocrinology·2024· 2 citedOpen Access
Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway
Biomedicine & Pharmacotherapy·2024· 11 citedOpen Access
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment
European Journal of Internal Medicine·2024· 14 cited
Empagliflozin restores autophagy and attenuates ponatinib-induced cardiomyocyte senescence and death
Vascular Pharmacology·2024· 3 cited
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
Biomedicine & Pharmacotherapy·2024· 12 citedOpen Access
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
2024Open Access
Vasostatins: new molecular targets for atherosclerosis, post-ischaemic angiogenesis, and arteriogenesis
Cardiovascular Research·2024· 7 cited
Development and Primary Characterization of a Human Thyroid Organoid in Vitro Model for Thyroid Metabolism Investigation
SSRN Electronic Journal·2024Open Access
Empagliflozin restores autophagy and ameliorates ponatinib-induced cardiomyocyte death
European Heart Journal·2023Open Access
CHICKEN HYPOCRETIN/OREXIN RECEPTORS ARE EXPRESSED LATER THAN THEIR ASSOCIATED NEURONS, BUT IN THE SAME AREAS AS IN RODENTS
IBRO Neuroscience Reports·2023Open Access
Antineoplastic drugs inducing cardiac and vascular toxicity – An update
Vascular Pharmacology·2023· 17 cited
page 1 of 6Next →

Frequent Co-authors

Riccardo Zucchi(36), Sabina Frascarelli(23), S Ronca-Testoni(14), Grazia Chiellini(13), Vittoria Carnicelli(11), Alessandro Saba(10), Rosalinda Madonna(10), Thomas S. Scanlan(6), Letizia Mattii(5), Leonardo Lorenzini(5), Ginevra Sacripanti(5), David K. Grandy(4), Stefania Moscato(4), Raffaele De Caterina(4), Grazia Chiellini(4), Francesca Ronca(4), Serena Barachini(4), Filippo Biondi(4), Simona Brogioni(3), Elisabetta Cerbai(3)